Calibr-Skaggs Institute for Innovative Medicines
La Jolla, California, United States
Purpose
to fund preclinical development of a long-acting oral formulation of EF-dA, either as a new chemical entity or as a prodrug, for pre-exposure prophylaxis of HIV infection to impact global health
Division
Global Health
Date
November 2018
Region Served
GLOBAL
Committed amount
$6,105,723
Grant topic
HIV
Duration (months)
54
Grantee location
La Jolla, California, United States
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.